Search

Search Constraints

You searched for: Author/Creator Campbell, Sorcha

Search Results

1. Adjuvant durvalumab post-chemoradiotherapy in stage III non-small cell lung cancer: experience from the Edinburgh Cancer Centre. (March 2022)

3. Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy. (March 2022)

4. Gross tumour volume predicts survival and correlates with pre-treatment serum albumin concentration in patients with stage III non-small cell lung cancer treated with chemo-radiotherapy. (March 2022)

5. Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?. (March 2022)

6. Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer. (June 2021)

7. The Scottish Inflammatory Prognostic Score (SIPS) identifies poor responders to first-line chemoimmunotherapy in non-small cell lung cancer. (March 2022)